Formulary: May 2024
Posted on April 26, 2024
Health New England’s formularies are located at healthnewengland.org. At the top of the page, use the “Find A Drug” tool.
| Medication | Changes |
|
Abiraterone |
edited policy to clarify that the 500mg tabs are excluded and that 250mg are the alternative, updated references and dates |
| Alosetron | added max dose restriction, updated references and dates |
| Arcalyst | added max dose restriction, updated references and dates |
|
Arikayce |
added max dose restriction, updated references and dates |
|
Bosulif |
updated age limitation to 1 year and older for chronic phase CML, added 50mg strength, updated references and dates |
|
Bylvay |
added new indication for alagille syndrome, updated references and dates |
|
Cayston |
added specialist criteria and max dose restriction, updated references and dates |
|
Cholbam |
changed initial duration of approval to 6 months, added quantity limits, updated
references and dates |
| Cosentyx 125mg/5ml | added new IV formulation to criteria |
|
Enbrel CM |
updated age limitation to 2 years and older for psoriatic arthritis, updated references and dates |
|
Ilaris |
added new indication of gout flares, added max dosing limitations, updated references and dates |
|
Livmarli |
updated age limitation to 3 months and older, updated references and dates |
| Medical Necessity CM | added clarifying compound criteria, updated references and dates |
|
Nexavar sorafenib |
added desmoid tumors as covered indication per NCCN guidelines, updated references and dates |
|
Reditrex CM |
Policy discontinued as product discontinued. |
|
Rinvoq CM |
minor grammatical changes, altered initial approval duration, updated references and dates |
|
Rozlytrek |
updated age to 1 month and older for solid tumors, added new strength to policy, updated references and dates |
|
Tarpeyo |
added lab result requirements, added that Tarpeyo is not to be used with Filspari,
updated references and dates |
|
Vancomycin 250mg |
added requirement to step through 125mg capsules first, updated references and dates |
| Vocabria | updated age limitation to 12 and older, updated references and dates |
|
Xalkori |
added new pellet formulation to criteria, updated ql based on indication, updated references and dates |
- The following Clinical Review Criteria Policies are new:
| Akeega |
| Augtyro |
| Daybue |
| Filspari |
| Fruzaqla |
| Joenja |
No Comments
Share:
